Cargando…
Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya.
We examined the long-term efficacy of praziquantel against Schistosoma haematobium, the causative agent of urinary schistosomiasis, during a school-based treatment program in the Msambweni area of Coast Province, Kenya, where the disease is highly endemic. Our results, derived from treating 4,031 of...
Autores principales: | King, C H, Muchiri, E M, Ouma, J H |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2640915/ https://www.ncbi.nlm.nih.gov/pubmed/11076716 |
Ejemplares similares
-
Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya.
por: Coles, G C, et al.
Publicado: (2001) -
Efficacy of Praziquantel against Schistosoma haematobium in Dulshatalo village, western Ethiopia
por: Mekonnen, Asaye, et al.
Publicado: (2013) -
Praziquantel, Mefloquine-Praziquantel, and Mefloquine-Artesunate-Praziquantel against Schistosoma haematobium: A Randomized, Exploratory, Open-Label Trial
por: Keiser, Jennifer, et al.
Publicado: (2014) -
Safety, efficacy and acceptability of praziquantel in the treatment of Schistosoma haematobium in pre-school children of Kwale County, Kenya
por: Kimani, Bridget W., et al.
Publicado: (2018) -
Efficacy and safety of praziquantel against Schistosoma haematobium in the Ikata-Likoko area of southwest Cameroon
por: Ebai, Calvin Bisong, et al.
Publicado: (2017)